IVIG has enhanced and even saved the lives of many autoimmune disease patients. But, the cost of therapy, large dose size and limited raw materials are serious limitations to an otherwise efficacious, well-tolerated therapy.
Current treatments for PANDAS have been shown to be relatively effective, but could surgical treatments such as tonsillectomy and adenoidectomy offer more effective results?
Still in its infancy, precision medicine holds out hope for moving directly from diagnosis to an effective tailor-fit treatment for each individual patient.
Influenza vaccination represents one of the most cost-effective treatment modalities available to the older adult population.
New long-acting therapeutics are changing the way hemophilia is managed, creating more choice and better treatment compliance.
Improving clinical trial enrollment numbers is a key challenge to advancing research, but a host of solutions suggests a new era of patient engagement and patient-focused clinical trials.
Usually developing following trauma, complex regional pain syndrome (CRPS) has been postulated to be associated with distal degeneration of small-diameter peripheral axons.
Baxalta’s BAX 855, a pegylated full-length recombinant factor VIII (rFVIII) based on the licensed rFVIII product Advate, was designed to increase half-life and potentially reduce the frequency of prophylactic infusions while maintaining hemostatic efficacy.
Investigators at Vanderbilt University Medical Center retrospectively extracted data from medical records of IBD patients treated with intravenous immune globulin (IVIG) used to treat these difficult cases.
The efficacy of Baxter International’s investigational recombinant von Willebrand factor (rVWF) was rated “excellent” (96.9%) or “good” (3.1%) for treatment of 192 bleeding events in 22 patients with severe von Willebrand disease who were enrolled in a Phase 3 clinical trial.
Will the evolving therapeutic guidelines for treating diabetes, as well as managing its risks and complications, stem the tide of this costly and sometimes deadly disease?
In results from a Phase 3b trial in 168 patients needing urgent reversal of acquired coagulation factor deficiency induced by vitamin K antagonist (VKA) therapy, 78 patients (90 percent) treated with CSL Behring’s four-factor prothrombin complex concentrate (Kcentra; 4F-PCC) achieved effective hemostasis, compared with 61 patients (75 percent) treated with plasma.